Futura Medical plc

Equities

FUM

GB0033278473

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:20 2024-04-29 am EDT			5-day change	1st Jan Change
34.85 ^GBX	-1.69%		-2.11%	+36.67%

Apr. 10	Futura Medical hails results as erectile dysfunction drug drives sales	AN
Apr. 10	Transcript : Futura Medical plc, 2023 Earnings Call, Apr 10, 2024

Futura Medical targets global expansion with Eroxon, eyeing profitability in 2024

April 11, 2024 at 07:12 am EDT

(via NewsDirect)

Futura Medical PLC (AIM:FUM, OTC:FAMDF) CEO James Barder tells Proactive's Stephen Gunnion about a strategic shift and refresh for the company in 2023, marked by the successful launch of Eroxon in the UK and Belgium, generating £3.1 million in revenues, FDA marketing authorisation in the US, and an exclusive marketing rights deal with Haleon for Eroxon in America.

These achievements have broadened Futura's global distribution network to approximately 80%, excluding China. The company aims to establish a new sexual health category within the OTC market, leveraging Futura's R&D expertise.

The specific launch date in the US with Haleon remains undisclosed due to competitive sensitivities, targeted within a year from the end of February. Pre-launch processes involve ensuring manufacturing capacity, engaging key opinion leaders, product positioning considering cultural sensitivities, and aligning with retailer schedules.

Objectives for this year include expanding into at least 14 new countries in the first half, exploring opportunities in Asia, particularly China, and extending Eroxon's product range while focusing on cost management.

Barder, reflecting on Futura's transition from a loss-making R&D firm to a pathway towards profitability, expresses optimism for continued progress in 2024.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

Latest news about Futura Medical plc

Futura Medical hails results as erectile dysfunction drug drives sales	Apr. 10	AN
Transcript : Futura Medical plc, 2023 Earnings Call, Apr 10, 2024	Apr. 10
Futura Medical plc Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 10	CI
Futura Medical's Eroxon to soon be available on prescription	Feb. 14	AN
BP and Prudential help snap FTSE losing streak	Feb. 06	AN
Futura Medical shares surge after "transformational year"	Feb. 06	AN
Futura Medical Extends License Deal with Cooper Consumer Health	Jan. 15	MT
Futura Medical extends licensing deal for erectile dysfunction gel	Jan. 15	AN
Futura Medical plc Extends Collaboration with Cooper Consumer Health	Jan. 15	CI
Futura Medical plc Announces Appointment of Roy Davis as Non-Executive Director	Jan. 09	CI
TRADING: Zambeef sees profit above market views; Luceco trades in line	Nov. 07	AN
Futura Medical, M8 Extend Deal to Offer Erectile Dysfunction Treatment in More Countries	Nov. 07	MT
Futura Medical, M8 Extend Deal to Offer Erectile Dysfunction Drug in More Countries	Nov. 07	MT
Futura Medical plc Expands Partnership with M8 Pharmaceuticals, Inc	Nov. 07	CI
Futura Medical gets Mexico marketing authorisation for Eroxon gel	23-10-25	AN
Eroxon® Granted Marketing Authorisation in Mexico	23-10-25	CI
Futura Medical launches erectile dysfunction gel in UAE	23-10-19	AN
UK’s Futura Medical Obtains EU Patent for Erectile Dysfunction Gel	23-10-02	MT
Futura Medical granted European patent for ED treatment	23-10-02	AN
Futura Medical plc Announces European Patent Office Grants Patent for Med3000	23-10-02	CI
Transcript : Futura Medical plc - Special Call	23-09-19
Elixirr record half-year revenue; Bango profit down	23-09-18	AN
Futura Medical plc Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-18	CI
Transcript : Futura Medical plc, H1 2023 Earnings Call, Sep 18, 2023	23-09-17
Futura Medical's ED treatment approved in Saudi Arabia	23-08-09	AN

Chart Futura Medical plc

Duration

Period

More charts

Company Profile

Futura Medical plc is a United Kingdom-based pharmaceutical company. The Company is engaged in the development and sale of pharmaceutical and healthcare products. It is focused on developing a portfolio of products based on its transdermal DermaSys technology. The DermaSys is designed to deliver clinically proven medical treatments via the skin. DermaSys platform with penetration and permeation enhancer components tailored for each product to suit the specific therapeutic indication and desired speed of onset and duration of action. Such targeted delivery offers an optimized profile in terms of dose, onset time and duration of effect. The Company's products include MED3000 and TPR100. The Company's lead product, MED3000, is a topical gel formulation treatment for erectile dysfunction (ED) through an evaporative mode of action. The Company has conducted a Phase III study using MED3000 in ED. The Company is also developing CBD100, which is a topical cannabidiol formulation.

Sector

Biotechnology & Medical Research

Calendar

2024-09-10 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.3545 GBP

Average target price

1.263 GBP

Spread / Average Target

+256.37%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
FUTURA MEDICAL PLC	+36.67%	133M
VERTEX PHARMACEUTICALS INCORPORATED	-2.53%	103B
REGENERON PHARMACEUTICALS, INC.	+1.72%	95.28B
ARGENX SE	+1.46%	22.15B
BIONTECH SE	-15.52%	21.02B
GENMAB A/S	-8.58%	18.15B
WUXI APPTEC CO., LTD.	-38.74%	16.73B
BEIGENE, LTD.	-12.54%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+5.50%	13.68B
SAREPTA THERAPEUTICS, INC.	+34.62%	12.17B

Bio Therapeutic Drugs